Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Down 87.4% in December

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 2,033 shares, a decline of 87.4% from the December 15th total of 16,171 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 6,747 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 6,747 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are sold short.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of institutional investors have recently modified their holdings of GNOM. IFP Advisors Inc boosted its position in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares in the last quarter. Oxinas Partners Wealth Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 12.1% in the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after purchasing an additional 1,751 shares during the last quarter. Atria Investments Inc raised its holdings in shares of Global X Genomics & Biotechnology ETF by 12.6% during the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after buying an additional 2,073 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 8.1% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after buying an additional 6,708 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Trading Up 0.7%

GNOM stock traded up $0.34 during trading hours on Wednesday, hitting $48.14. 2,370 shares of the stock were exchanged, compared to its average volume of 11,286. Global X Genomics & Biotechnology ETF has a 12 month low of $27.20 and a 12 month high of $48.92. The firm has a market capitalization of $54.40 million, a P/E ratio of -20.57 and a beta of 1.22. The company has a 50-day simple moving average of $45.77 and a two-hundred day simple moving average of $40.69.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were given a dividend of $0.5912 per share. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio is currently -26.50%.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.